| Literature DB >> 35055194 |
Dušan S Dimić1, Goran N Kaluđerović2, Edina H Avdović3, Dejan A Milenković3, Marko N Živanović3, Ivan Potočňák4, Erika Samoľová5, Milena S Dimitrijević6, Luciano Saso7, Zoran S Marković3, Jasmina M Dimitrić Marković1.
Abstract
In this contribution, four new compounds synthesized from 4-hydroxycoumarin and tyramine/octopamine/norepinephrine/3-methoxytyramine are characterized spectroscopically (IR and NMR), chromatographically (UHPLC-DAD), and structurally at the B3LYP/6-311++G*(d,p) level of theory. The crystal structure of the 4-hydroxycoumarin-octopamine derivative was solved and used as a starting geometry for structural optimization. Along with the previously obtained 4-hydroxycoumarin-dopamine derivative, the intramolecular interactions governing the stability of these compounds were quantified by NBO and QTAIM analyses. Condensed Fukui functions and the HOMO-LUMO gap were calculated and correlated with the number and position of OH groups in the structures. In vitro cytotoxicity experiments were performed to elucidate the possible antitumor activity of the tested substances. For this purpose, four cell lines were selected, namely human colon cancer (HCT-116), human adenocarcinoma (HeLa), human breast cancer (MDA-MB-231), and healthy human lung fibroblast (MRC-5) lines. A significant selectivity towards colorectal carcinoma cells was observed. Molecular docking and molecular dynamics studies with carbonic anhydrase, a prognostic factor in several cancers, complemented the experimental results. The calculated MD binding energies coincided well with the experimental activity, and indicated 4-hydroxycoumarin-dopamine and 4-hydroxycoumarin-3-methoxytyramine as the most active compounds. The ecotoxicology assessment proved that the obtained compounds have a low impact on the daphnia, fish, and green algae population.Entities:
Keywords: DFT; X-ray crystallography; coumarin; molecular docking; molecular dynamics; neurotransmitter
Mesh:
Substances:
Year: 2022 PMID: 35055194 PMCID: PMC8780855 DOI: 10.3390/ijms23021001
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Scheme 1Synthesis of coumarin-neurotransmitters derivatives (L1–L5) from 3-acetyl-4-hydroxycoumarin (1) and respective neurotransmitters and their metabolites (2).
Crystal data and structure refinement of L2.
| Compound | L2 |
|---|---|
| Empirical formula | C19H17NO5 |
| Formula weight | 339.33 |
| Temperature | 95(2) K |
| Wavelength | 1.54184 Å |
| Crystal system | Triclinic |
| Unit cell dimensions | |
| Volume | 797.94(4) Å3 |
| 2; 1.412 g cm−3 | |
| Absorption coefficient | 0.855 mm−1 |
| 356 | |
| Crystal shape, color | prism, colorless |
| Crystal size | 0.234 × 0.066 × 0.044 mm3 |
| 3.633–74.514° | |
| Index ranges | −7 ≤ |
| Reflections collected/independent | 12478/3213 [ |
| Data/restraints/parameters | 3213/0/248 |
| Goodness-of-fit on | 1.027 |
| Final | |
| Largest diff. peak and hole | 0.394; −0.486 e Å−3 |
Figure 1Molecular structure with the atom numbering scheme of L2. Displacement ellipsoids are drawn at 50% probability; hydrogen bonds are shown as red dashed lines. The disordered parts of hydroxy and methyl groups are shown in lighter colors.
Hydrogen bonds for L2 [Å and °].
| D−H···A | d(D−H) | d(H···A) | d(D···A) | <(DHA) |
|---|---|---|---|---|
| C2′−H2’A···O2 | 0.98 | 1.90 | 2.709(2) | 138.5 |
| C7″−H7”···O41 i | 0.95 | 2.38 | 3.235(4) | 149.3 |
| N1−H1N1···O3 | 0.92(3) | 1.80(3) | 2.5909(19) | 142(2) |
| O5−H1O5···O2 ii | 0.83(3) | 1.92(4) | 2.7236(19) | 161(3) |
| O41−H1O4···O3 iii | 0.92(4) | 1.93(4) | 2.797(2) | 158(3) |
Symmetry transformations used to generate equivalent atoms: (i): x + 1, y, z; (ii): x + 1, y, z + 1; (iii): −x + 1, −y + 1, −z + 1.
Figure 2A layer parallel with the ac plane in the crystal structure of L2 is formed by hydrogen bonds (red dashed lines) viewed along the a-axis.
Experimental and theoretical (at B3LYP-D3BJ/6-311++G(d,p), GIAO method) chemical shifts of L2. The enumeration follows Figure 1.
| δ(1H) (ppm) | δ(13C) (ppm) | ||||
|---|---|---|---|---|---|
| Experimental | Theoretical | Experimental | Theoretical | ||
| C2′–H(3) | 2.5 | 2.6 | C2′ | 18.6 | 22.2 |
| C1″–H(2) | 3.4 | 3.8 | C1″ | 51.6 | 53.8 |
| O5–H | 4.8 | 4.8 | C2″ | 70.2 | 75.2 |
| C2″–H | 5.8 | 5.1 | C3 | 96.1 | 98.1 |
| C7″–H | 6.7 | 7.1 | C7″ | 115.0 | 113.2 |
| C5″–H | 6.7 | 7.1 | C5″ | 115.0 | 114.4 |
| C6–H | 7.3 | 7.6 | C8 | 116.2 | 116.1 |
| C8–H | 7.3 | 7.6 | C10 | 120.4 | 119.9 |
| C8″–H | 7.3 | 7.6 | C6 | 123.6 | 122.7 |
| C7–H | 7.6 | 7.8 | C5 | 125.7 | 125.9 |
| C4″–H | 7.9 | 7.9 | C4″ | 127.3 | 127.4 |
| C5–H | 9.4 | 8.5 | C8″ | 127.3 | 129.3 |
| N1–H | 13.8 | 13.6 | C7 | 132.7 | 133.9 |
| MAE (ppm) | 0.3 | C3″ | 133.9 | 134.8 | |
| C9 | 153.1 | 153.6 | |||
| C6″ | 156.8 | 156.5 | |||
| C2 | 162.0 | 159.9 | |||
| C1′ | 176.0 | 174.7 | |||
| C4 | 179.4 | 177.4 | |||
| MAE (ppm) | 1.4 | ||||
Figure 3Optimized geometries of the coumarin-neurotransmitter derivatives (at B3LYP-D3BJ/6-311++G(d,p) level of theory).
The interaction energies, electron density, and Laplacian of the intramolecular interactions.
| O–C–C–C–N–H | Aromatic Ring Substituents | |||
|---|---|---|---|---|
| Compound | Interaction Energy | Electron Density [a.u.] | Laplacian [a.u.] | Interaction Energy |
|
| LP(O)→σ(N–H), 102 | 0.057 | 0.166 | / |
|
| LP(O)→σ(N–H), 86 | 0.052 | 0.158 | / |
|
| LP(O)→σ(N–H), 87 | 0.052 | 0.158 | LP(O)→σ(O–H), 4 |
|
| LP(O)→σ(N–H), 93 | 0.055 | 0.162 | LP(O)→σ(O–H), 17 |
|
| LP(O)→σ(N–H), 102 | 0.056 | 0.163 | LP(O)→σ(O–H), 2 |
The cytotoxic effects of L1, L2, L3, L4, and L5 after 24 and 72 h of exposure.
| IC₅₀, µM | HCT-116 | HeLa | MDA-MB-231 | MRC-5 | ||||
|---|---|---|---|---|---|---|---|---|
| 24 h | 72 h | 24 h | 72 h | 24 h | 72 h | 24 h | 72 h | |
|
| >500 | 170 | >500 | 452 | >500 | >500 | ||
|
| 248 | 206 | ||||||
|
| 107 | 495 | ||||||
|
| 74 | 150 | ||||||
|
| 73 | 92 | ||||||
Figure 4Predicted binding interactions between the investigated molecules and the hCA-IX receptor.
The important thermodynamic parameters for the best docking conformations of the investigated molecules with the hCA-IX receptor (PDB ID: 3IAI).
| Conformations | ΔGbind | Ki | ΔGvdw+hbond+desolv | ΔGelec | ΔGtotal | ΔGtor | ΔGunb |
|---|---|---|---|---|---|---|---|
| hCA-IX- | −37.8 | 237.83 | −39.9 | 0.3 | −2.3 | 2.8 | 0.0 |
| hCA-IX- | −41.2 | 60.4 | −38.8 | −0.5 | −6.7 | 4.8 | 0.0 |
| hCA-IX- | −39.8 | 107.8 | −39.1 | −0.3 | −6.1 | 5.7 | 0.0 |
| hCA-IX- | −41.9 | 45.2 | −39.5 | −0.3 | −8.7 | 6.7 | 0.0 |
| hCA-IX- | −42.1 | 41.8 | −41.0 | 0.2 | −7.0 | 5.7 | 0.0 |
| hCA-IX- | −43.7 | 21.9 | −39.5 | −1.0 | −9.0 | 5.7 | 0.0 |
Figure 5The plot of root mean square deviation (RMSD) of the C–Cα–N backbone vs. simulation time for solvated hCA-IX in complex with all coumarin-neurotransmitter derivatives during 20 ns molecular dynamics simulations.
Figure 6The root mean square fluctuation (RMSF) values of hCA-IX in complex with the investigated candidate compounds plotted against residue numbers.
Important thermodynamic parameters generated by the MM/PBSA protocol.
| Complex | ΔEelec | ΔEVDW | ΔGpolar | ΔGnonpolar | ΔGbinding |
|---|---|---|---|---|---|
| hCA-IX- | −338.9 ± 27.7 | −105.9 ± 14.4 | 393.6 ± 27.0 | −17.2 ± 1.1 | −68.4 ± 52.2 |
| hCA-IX- | −333.4 ± 21.2 | −116.0 ± 18.1 | 419.8 ± 29.3 | −18.3 ± 1.1 | −47.8 ± 39.8 |
| hCA-IX- | −27.1 ± 27.0 | −94.9 ±16.4 | 59.0 ± 17.9 | −13.0 ± 1.2 | −75.9 ± 24.3 |
| hCA-IX- | −167.9 ± 1.4 | −138.7 ± 1.2 | 141.1 ± 1.3 | −19.3 ± 0.1 | −184.9 ± 1.3 |
| hCA-IX- | −351.0 ± 26.6 | −135.4 ± 16.5 | 316.1 ± 26.6 | −19.5 ± 1.2 | −189.7 ± 27.1 |
Toxicity evaluation of the coumarin-neurotransmitter derivatives (mg L−1).
| Compound | LC50 | LC50 | EC50 | ChV | ChV | ChV |
|---|---|---|---|---|---|---|
|
| 424 | 96.3 | 35.3 | 36.3 | 8.2 | 53.4 |
|
| 5080 | 576 | 399 | 372 | 37.6 | 419 |
|
| 2150 | 66,400 | 109 | 2000 | 30,600 | 8.78 |
|
| 611 | 128 | 50.6 | 51.4 | 10.6 | 73.3 |
|
| 249 | 4170 | 31.5 | 184 | 1750 | 3.18 |